Updates are available Correction dated 2022-01-19
Click to view Correction: https://doi.org/10.1038/s41433-021-01914-2
-
Authors
Phillips, Mark R. http://orcid.org/0000-0003-0923-261X
Wykoff, Charles C.
Thabane, Lehana http://orcid.org/0000-0003-0355-9734
Bhandari, Mohit http://orcid.org/0000-0001-9608-4808
Chaudhary, Varun http://orcid.org/0000-0002-9988-4146
,
Sivaprasad, Sobha
Kaiser, Peter
Sarraf, David
Bakri, Sophie J.
Garg, Sunir J.
Singh, Rishi P.
Holz, Frank G.
Wong, Tien Y.
Guymer, Robyn H.
- License Information
-
More Information
Article History
Received: 11 November 2021
Revised: 12 November 2021
Accepted: 15 November 2021
First Online: 26 November 2021
Change Date: 19 January 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41433-021-01914-2
Competing interests
: MRP: Nothing to disclose. CCW: Consultant: Acuela, Adverum Biotechnologies, Inc, Aerpio, Alimera Sciences, Allegro Ophthalmics, LLC, Allergan, Apellis Pharmaceuticals, Bayer AG, Chengdu Kanghong Pharmaceuticals Group Co, Ltd, Clearside Biomedical, DORC (Dutch Ophthalmic Research Center), EyePoint Pharmaceuticals, Gentech/Roche, GyroscopeTx, IVERIC bio, Kodiak Sciences Inc, Novartis AG, ONL Therapeutics, Oxurion NV, PolyPhotonix, Recens Medical, Regeron Pharmaceuticals, Inc, REGENXBIO Inc, Santen Pharmaceutical Co, Ltd, and Takeda Pharmaceutical Company Limited; Research funds: Adverum Biotechnologies, Inc, Aerie Pharmaceuticals, Inc, Aerpio, Alimera Sciences, Allergan, Apellis Pharmaceuticals, Chengdu Kanghong Pharmaceutical Group Co, Ltd, Clearside Biomedical, Gemini Therapeutics, Genentech/Roche, Graybug Vision, Inc, GyroscopeTx, Ionis Pharmaceuticals, IVERIC bio, Kodiak Sciences Inc, Neurotech LLC, Novartis AG, Opthea, Outlook Therapeutics, Inc, Recens Medical, Regeneron Pharmaceuticals, Inc, REGENXBIO Inc, Samsung Pharm Co, Ltd, Santen Pharmaceutical Co, Ltd, and Xbrane Biopharma AB—unrelated to this study. LT: Nothing to disclose. MB: Research funds: Pendopharm, Bioventus, Acumed – unrelated to this study. VC: Advisory Board Member: Alcon, Roche, Bayer, Novartis; Grants: Bayer, Novartis – unrelated to this study.
Free to read: This content has been made available to all.
